AMGN241115P335000
- 40.15
- +27.10+207.66%
Amgen Newsroom
Amgen To Go Ex-Dividend On November 18th, 2024 With 2.25 USD Dividend Per Share
November 14th (Eastern Time) - $Amgen(AMGN.US)$ is trading ex-dividend on November 18th, 2024.Shareholders of record on November 18th, 2024 will receive 2.25 USD dividend per share on December 9th, 20
Wolfe Research Maintains Amgen(AMGN.US) With Hold Rating
Express News | Amgen Presents New Data Across Rare Inflammatory Diseases at Acr 2024
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
5 Healthcare Stocks to Buy in a Beaten-Up Sector -- Barrons.com
Dow's 111-Point Drop Led By Losses For Salesforce, Cisco Stocks
Amgen's Options Frenzy: What You Need to Know
Evercore Maintains Amgen(AMGN.US) With Buy Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $383
Today's Analyst Rating | NVIDIA Price Target Raised to $175 by Oppenheimer, Amazon Price Target Raised to $250 by Needham
Nov 14, Wall Street analysts have updated their stock ratings today including $NVIDIA(NVDA.US)$ and $Amazon(AMZN.US)$.
Amgen Analyst Ratings
Express News | Amgen Inc : Citigroup Initiates Coverage With Neutral Rating; Price Target $335
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Express News | Amgen Exec Says Some Supplemental Maritide Data Published Were Not Subject to Our Standard Institutional Review,
Express News | Amgen Exec Says Believe That a Research Note Had Suggested "an Inappropriate Inference" of Maritide Data Given Its Limitations
Express News | Amgen Exec Says Co Has Not Seen Any Association Between Administration of Maritide and Bone Mineral Density Changes or Safety Signals for Bone
Express News | Amgen Exec Says Co Continues to Be "Laser Focused" on a Phase Three Development Program for Its Obesity Drug Maritide - UBS Healthcare Conference